Oncolys BioPharma Inc. (4588.T)
JPY 574.0
(1.59%)
JPY 574.0
(1.59%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 30.6 Million JPY | -90.96% |
| 2022 | 338.48 Million JPY | 70.26% |
| 2021 | 198.8 Million JPY | -15.8% |
| 2020 | 236.11 Million JPY | -80.17% |
| 2019 | 1.19 Billion JPY | 2422.22% |
| 2018 | 47.21 Million JPY | -70.04% |
| 2017 | 157.58 Million JPY | -11.62% |
| 2016 | 178.29 Million JPY | 47.0% |
| 2015 | 121.28 Million JPY | 327.02% |
| 2014 | 28.4 Million JPY | 2391.49% |
| 2013 | 1.14 Million JPY | -99.71% |
| 2012 | 396.75 Million JPY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | - JPY | 100.0% |
| 2024 Q2 | 31.38 Million JPY | 0.0% |
| 2023 Q4 | -1.6 Million JPY | -197.96% |
| 2023 FY | 30.6 Million JPY | -90.96% |
| 2023 Q1 | 2.56 Million JPY | -90.94% |
| 2023 Q2 | 27.89 Million JPY | 986.75% |
| 2023 Q3 | -539 Thousand JPY | -101.93% |
| 2022 FY | 338.48 Million JPY | 70.26% |
| 2022 Q2 | 111.97 Million JPY | -12.17% |
| 2022 Q1 | 127.48 Million JPY | 333.28% |
| 2022 Q4 | 28.33 Million JPY | -59.92% |
| 2022 Q3 | 70.69 Million JPY | -36.86% |
| 2021 Q3 | 29.83 Million JPY | -73.45% |
| 2021 Q4 | 29.42 Million JPY | -1.36% |
| 2021 Q1 | 27.17 Million JPY | -73.57% |
| 2021 Q2 | 112.37 Million JPY | 313.51% |
| 2021 FY | 198.8 Million JPY | -15.8% |
| 2020 Q3 | 31.84 Million JPY | -37.17% |
| 2020 Q4 | 102.81 Million JPY | 222.82% |
| 2020 FY | 236.11 Million JPY | -80.17% |
| 2020 Q2 | 50.68 Million JPY | -0.16% |
| 2020 Q1 | 50.76 Million JPY | -91.68% |
| 2019 FY | 1.19 Billion JPY | 2422.22% |
| 2019 Q1 | 6.84 Million JPY | -62.43% |
| 2019 Q3 | 10.82 Million JPY | -98.08% |
| 2019 Q2 | 563.32 Million JPY | 8126.11% |
| 2019 Q4 | 609.94 Million JPY | 5533.03% |
| 2018 Q3 | 8.55 Million JPY | -43.29% |
| 2018 Q4 | 18.22 Million JPY | 113.06% |
| 2018 Q2 | 15.08 Million JPY | 181.91% |
| 2018 FY | 47.21 Million JPY | -70.04% |
| 2018 Q1 | 5.35 Million JPY | -95.96% |
| 2017 Q4 | 132.52 Million JPY | 2467.28% |
| 2017 FY | 157.58 Million JPY | -11.62% |
| 2017 Q1 | 15.38 Million JPY | -88.33% |
| 2017 Q2 | 4.51 Million JPY | -70.63% |
| 2017 Q3 | 5.16 Million JPY | 14.28% |
| 2016 Q4 | 131.76 Million JPY | 6984.14% |
| 2016 Q3 | 1.86 Million JPY | -87.7% |
| 2016 Q1 | 29.55 Million JPY | -70.85% |
| 2016 FY | 178.29 Million JPY | 47.0% |
| 2016 Q2 | 15.12 Million JPY | -48.84% |
| 2015 Q1 | 2.13 Million JPY | -90.01% |
| 2015 FY | 121.28 Million JPY | 327.02% |
| 2015 Q4 | 101.36 Million JPY | 742.98% |
| 2015 Q3 | 12.02 Million JPY | 108.77% |
| 2015 Q2 | 5.76 Million JPY | 170.04% |
| 2014 FY | 28.4 Million JPY | 2391.49% |
| 2014 Q2 | 1.85 Million JPY | -19.33% |
| 2014 Q3 | 2.9 Million JPY | 56.27% |
| 2014 Q4 | 21.34 Million JPY | 635.42% |
| 2014 Q1 | 2.3 Million JPY | 107.2% |
| 2013 FY | 1.14 Million JPY | -99.71% |
| 2013 Q4 | 1.11 Million JPY | 0.0% |
| 2012 FY | 396.75 Million JPY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.88 Billion JPY | 98.373% |
| PRISM BioLab Co.,LTD | 80.3 Million JPY | 61.89% |
| GNI Group Ltd. | 22.43 Billion JPY | 99.864% |
| Linical Co., Ltd. | 3.77 Billion JPY | 99.19% |
| Trans Genic Inc. | 2.24 Billion JPY | 98.639% |
| MEDINET Co., Ltd. | 98.25 Million JPY | 68.851% |
| Soiken Holdings Inc. | 2.48 Billion JPY | 98.767% |
| Cytori Cell Research Institute, Inc. | 1.29 Billion JPY | 97.632% |
| AnGes, Inc. | -3.06 Billion JPY | 100.998% |
| OncoTherapy Science, Inc. | -177.71 Million JPY | 117.221% |
| Nxera Pharma Co., Ltd. | 9.66 Billion JPY | 99.683% |
| Immuno-Biological Laboratories Co., Ltd. | 517.29 Million JPY | 94.084% |
| NanoCarrier Co., Ltd. | 110.95 Million JPY | 72.417% |
| Carna Biosciences, Inc. | 1.45 Billion JPY | 97.89% |
| CanBas Co., Ltd. | -984 Million JPY | 103.11% |
| D. Western Therapeutics Institute, Inc. | 391.69 Million JPY | 92.187% |
| RaQualia Pharma Inc. | 1.65 Billion JPY | 98.152% |
| Chiome Bioscience Inc. | 398.59 Million JPY | 92.322% |
| Kidswell Bio Corporation | 1.03 Billion JPY | 97.055% |
| PeptiDream Inc. | 17.21 Billion JPY | 99.822% |
| Ribomic Inc. | -10.5 Million JPY | 391.421% |
| SanBio Company Limited | -14.5 Million JPY | 311.011% |
| Healios K.K. | 108 Million JPY | 71.662% |
| BrightPath Biotherapeutics Co., Ltd. | -341 Thousand JPY | 9075.073% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -59.04 Million JPY | 151.832% |
| Delta-Fly Pharma, Inc. | -1.51 Million JPY | 2124.14% |
| StemRIM | -44.34 Million JPY | 169.009% |
| CellSource Co., Ltd. | 3.18 Billion JPY | 99.039% |
| FunPep Company Limited | -680.28 Million JPY | 104.499% |
| Kringle Pharma, Inc. | 69.25 Million JPY | 55.805% |
| Stella Pharma Corporation | 217.29 Million JPY | 85.916% |
| TMS Co., Ltd. | -6.95 Million JPY | 540.36% |
| Noile-Immune Biotech Inc. | 314.56 Million JPY | 90.271% |
| Cuorips Inc. | 9.63 Million JPY | -217.776% |
| K Pharma,Inc. | 910 Million JPY | 96.637% |
| Takara Bio Inc. | 25.45 Billion JPY | 99.88% |
| ReproCELL Incorporated | 1.1 Billion JPY | 97.23% |
| PhoenixBio Co., Ltd. | 1.19 Billion JPY | 97.439% |
| StemCell Institute Inc. | 1.57 Billion JPY | 98.058% |
| Japan Tissue Engineering Co., Ltd. | 1.66 Billion JPY | 98.164% |
| CellSeed Inc. | 107.15 Million JPY | 71.439% |